Abstract:The bovine spongiform encephalopathy (BSE) epidemic, along with the related threat to human health posed by the transmission of the BSE agent to humans, has highlighted the importance of prion diseases. These fatal neurodegenerative diseases are characterised by spongiform changes in the CNS, and comprise a wide spectrum of clinicopathological entities in humans and animals, such as Creutzfeldt-Jakob disease (CJD) and its emerging new variant (vCJD) in humans, and BSE and scrapie in animals. This article reviews the geographical distribution and the temporal trends of CJD and vCJD; the major events in the pathogenesis of prion diseases; the risk factors for sporadic CJD and vCJD; and the possible strategies for treating them. Worldwide statistics indicate that sporadic CJD has a stable incidence of one case per million people per year; in contrast, the incidence of vCJD appears to have increased exponentially from its characterisation in 1994 to a peak in 2000. As of December 2005, 183 definite or probable cases of vCJD had been reported worldwide. The crucial event in the pathogenesis of prion diseases is the conversion of the normally occurring cellular prion protein (PrP(c)) into a pathogenic form, called protease-resistant PrP (PrP(res)) or scrapie PrP (PrP(sc)). Pathogenetic studies in rodent models have shown that PrP(sc) is found in the enteric nervous system and in the gut-associated lymphoid tissue following oral scrapie ingestion. The role of the lymphoreticular system in the pathogenesis of TSE seems to be related to the strains of agents and the host genotype. Therapeutic approaches to vCJD are mainly based on the inhibition or prevention of the pathological change that creates PrP(sc). Derivatives of acridine (such as mepacrine [quinacrine]) and the phenothiazine psychotropics have been proposed as possible therapies because of their activity in cellular models; however, neither class was able to affect the protease resistance of preexisting PrP fibrils. More encouragingly, in animal models of prion disease, tetracyclines were found to reduce prion infectivity by direct inactivation of PrP(sc). While these findings are promising, the suitability of these compounds for clinical use is still limited by their low efficacy once symptoms are apparent. Treatments based on the vaccination approach have also produced positive results, but further investigations are necessary to establish their clinical application.

Is vaccination against transmissible spongiform encephalopathy feasible?

Immunomodulation for prion and prion-related diseases

Vaccines for prion diseases: a realistic goal?

Prospects for preventative vaccines against prion diseases

Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes

Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances

Expression of PrP(C) As HIS-fusion Form in a Baculovirus System and Conversion of Expressed PrP-sen to PrP-res in a Cell-Free System.

Oral vaccination as a potential strategy to manage chronic wasting disease in wild cervid populations

Interactions between Cytokines and the Pathogenesis of Prion Diseases: Insights and Implications

Understanding Intra-Species and Inter-Species Prion Conversion and Zoonotic Potential Using Protein Misfolding Cyclic Amplification

Prions and protein-folding diseases

PrP(Sc) of Scrapie 263K Propagates Efficiently in Spleen and Muscle Tissues with Protein Misfolding Cyclic Amplification.

Recombinant prion protein vaccination of transgenic elk PrP mice and reindeer overcomes self-tolerance and protects mice against chronic wasting disease

New implications for prion diseases therapy and prophylaxis

Prion therapeutics: Lessons from the past

Prions, BSE and food

Human prion disease: molecular pathogenesis, and possible therapeutic targets and strategies

The importance of ongoing international surveillance for Creutzfeldt–Jakob disease

Variant Creutzfeldt-Jakob disease: pathology, epidemiology, and public health implications

The importance of prion research

Preclinical transmission of prions by blood transfusion is influenced by donor genotype and route of infection